Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

EOS imaging Enters the North African Market with the First Two EOS Systems in Tunisia

EOS imaging
Posted on: 13 Oct 16

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today the recent entry into the North African market with the opening of two EOS sites in Tunisia. The systems are operated by the public Institut Mohamed Kassab d’Orthopédie and the private Centre d'Imagerie Médicale Ariana in the Tunis metropolitan area. The Institut Mohamed Kassab d’Orthopédie is a center of excellence in Tunisia for orthopedic surgery, treating adults and children with advanced techniques. The Centre d'Imagerie Médicale Ariana, founded in 1992, has a comprehensive radiological suite, including numerous modalities and a staff of 30, of which 4 are radiologists.

EOS imaging will also be attending the Journées Francophones de Radiologie (JFR) meeting, to be held October 14-17 in Paris, France. JFR is the second largest gathering of radiologists in Europe and attracts over 17,000 attendees from 80 different countries, including numerous physicians from Africa. During the JFR meeting, EOS imaging will share with radiologists its solutions to increase the role of image-based reports and data in the orthopedic care pathways. This includes, next to the Company’s biplanar low dose equipment: easy access to 3D models and patient-specific data sets through the new EOS 3D services suite; tools for seamless exchange between radiologists and referring orthopedic surgeons; and on line 3D surgical planning solutions (EOSapps) for the spine, hip and knee. Demonstrations of the products will be available at the Company’s booth #113.

Marie Meynadier, CEO of EOS imaging, said, “It’s always exciting when an up-and-coming market adopts the EOS technology. With the opening of these two new sites in Tunisia, providers in North Africa will now have access to reference centers to learn about EOS as they are looking to equip their imaging departments with state of the art, safe and precise imaging. The JFR meeting is also a great forum for sharing with radiologists from Europe and Africa our newest developments and contribute to the strengthening of their relationships with referring surgeons.”

For more information, please visit www.eos-imaging.com.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

About EOS imaging

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States, Japan, China, and the European Union. The Group posted 2015 revenues of €21.8 million and employs 122 people. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

Next press release: 2016 Third-quarter sales: Thursday October 27, 2016 (after market close)

View source version on businesswire.com: http://www.businesswire.com/news/home/20161013006196/en/

Business Wire
www.businesswire.com

Last updated on: 13/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.